Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

The Lancet. Diabetes & Endocrinology
Kohjiro UekiJ-DOIT3 Study Group

Abstract

Limited evidence suggests that multifactorial interventions for control of glucose, blood pressure, and lipids reduce macrovascular complications and mortality in patients with type 2 diabetes. However, safe and effective treatment targets for these risk factors have not been determined for such interventions. In this multicentre, open-label, randomised, parallel-group trial, undertaken at 81 clinical sites in Japan, we randomly assigned (1:1) patients with type 2 diabetes aged 45-69 years with hypertension, dyslipidaemia, or both, and an HbA1c of 6·9% (52·0 mmol/mol) or higher, to receive conventional therapy for glucose, blood pressure, and lipid control (targets: HbA1c <6·9% [52·0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease]) or intensive therapy (HbA1c <6·2% [44·3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease]). Randomisation was done using a computer-generated, dynamic balancing method, stratified by sex, age, HbA1c, and history of cardiovascular disease. Neither patients nor investigators were masked to group assignment. The primary outcome was ...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jan 7, 2006·Nature Medicine·Yoshio Yazaki, Takashi Kadowaki
Oct 6, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Fumio ObaraKazuaki Shimamoto
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Feb 20, 2009·Journal of the American Society of Nephrology : JASN·Bastiaan E de GalanUNKNOWN ADVANCE Collaborative Group
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
May 29, 2010·Diabetes Care·Cyrus V DesouzaVivian Fonseca
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
Jan 11, 2013·Kidney International·Vlado PerkovicUNKNOWN ADVANCE Collaborative Group
Apr 18, 2014·The New England Journal of Medicine·Edward W GreggLinda Geiss
Feb 11, 2015·JAMA : the Journal of the American Medical Association·Connor A EmdinAnushka Patel
Feb 18, 2016·The New England Journal of Medicine·Walter N KernanUNKNOWN IRIS Trial Investigators

❮ Previous
Next ❯

Citations

Jun 5, 2019·Journal of Stroke·Chang Ho Ahn, Soo Lim
Jun 3, 2020·The Journal of Clinical Endocrinology and Metabolism·Silvio E InzucchiBernard Zinman
Apr 21, 2020·American Journal of Hypertension·Waleed Ali, George L Bakris
Aug 30, 2020·European Heart Journal·Jean-Philippe ColletUNKNOWN ESC Scientific Document Group
May 22, 2018·Internal Medicine·Ippei Kanazawa, Toshitsugu Sugimoto
May 26, 2018·Expert Opinion on Pharmacotherapy·Nobuya InagakiHiroaki Iijima
Jul 18, 2019·Journal of General and Family Medicine·Masayuki Ikeda, Rumiko Shimazawa
Feb 27, 2020·Biomedicines·Keiichiro MatobaRimei Nishimura
May 23, 2020·Clinical Epidemiology·Jes Sanddal LindholtAxel Cosmus Pyndt Diederichsen
Apr 24, 2018·Annals of Vascular Diseases·Kazuya Fujihara, Hirohito Sone
Apr 28, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Hirotoshi OhmuraUNKNOWN SPIRITS-J Study Investigators
Mar 17, 2018·American Journal of Hypertension·Darshan KhanguraJames R Sowers
Jul 15, 2018·Clinical and Experimental Nephrology·Eiichiro KandaUNKNOWN Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease
Sep 21, 2018·Cardiovascular Diabetology·Dennis KannenkerilRoland E Schmieder
Oct 26, 2018·Cardiovascular Diabetology·Mathilde NativelKamel Mohammedi
Aug 4, 2019·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Satoshi UmemuraNobuhito Hirawa
Jul 12, 2019·Endocrinology, Diabetes & Metabolism·Yuki FujiwaraKinsuke Tsuda
Apr 18, 2019·The Journal of Clinical Endocrinology and Metabolism·Mayuko Yamada-HaradaHirohito Sone
Aug 10, 2019·Geriatrics & Gerontology International·Masafumi Kuzuya
Mar 13, 2019·American Journal of Physiology. Endocrinology and Metabolism·Masakazu KoshibuTsutomu Hirano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.